OHC doctors are evaluating two new treatments for classic Hodgkin lymphoma that may offer fewer, milder side effects.

Miguel Islas-Ohlmayer, MD, Medical Oncologist, Hematologist, and Transplant Specialist at OHC

Classical Hodgkin lymphoma (CHL) is considered a highly treatable blood cancer. Advancements in diagnosis and treatment have helped give people with this disease the chance for a full recovery. However, 20 percent of CHL patients do not respond... Read More

Pink Ribbon Girls Helps When Cancer Makes Daily Activities a Challenge

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

For women who receive a breast cancer diagnosis, OHC will lead you through your cancer journey and surround you with the treatments and services you need to beat your disease. Some patients may experience fatigue and nausea from the treatment, which... Read More

Unique program pairs cancer patients with cancer survivors who’ve “been there.”

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

Paige Shapiro is one of the fortunate ones. She has survived ovarian cancer. This year in the U.S., approximately 14,000 women will not be as fortunate as Paige. They will lose their battle with ovarian cancer, mostly due to the lack of an early... Read More

OHC is helping tackle the ongoing challenges of ovarian cancer

Marcia C. Bowling, MD, Gynecologic Oncologist with OHC

During my career as a gynecologic oncologist with OHC, my colleagues and I have seen some remarkable advancements in the treatment of ovarian cancer. This includes the introduction of robotic-assisted surgery, new FDA-approved drugs, and promising... Read More

Cancer Doctors Warn Thirty-somethings: Be Aware of Testicular Cancer

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

Testicular cancer is one of the most commonly diagnosed cancers in young adult men, particularly between ages 30 to 39. If the cancer hasn’t spread, the survival rate is 99%. However, once it has spread to other organs, the survival rate drops to... Read More

Cancer Experts at OHC are Evaluating a New Treatment for Older Adults with Acute Myeloid Leukemia

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

Although acute myeloid leukemia (AML) accounts for only about one percent of all cancers, it can be deadly if not treated. Approximately two out of three people with AML who receive standard chemotherapy go into remission. The chance of remission... Read More

OHC is Offering a New Treatment for Men with Advanced Prostate Cancer

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

Prostate cancer is the second most common cancer among men. The good news is that approximately 90 percent of prostate cancers are diagnosed in early stages and the survival rate at this stage is nearly 100 percent. But for the patients who are... Read More

OHC Evaluating New Treatment for Older Adults with Hodgkin Lymphoma

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

Survival rates for patients with Hodgkin lymphoma have improved in the past few decades, largely due to advancements in treatment. The five-year relative survival rate for all patients diagnosed with Hodgkin lymphoma is now approximately 87 percent.... Read More

Local Doctors Are Evaluating a Promising New Treatment for Kidney Cancer

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

The American Cancer Society estimates that approximately 25 percent of people diagnosed with kidney (renal) cancer in the U.S. will die from the disease. This number has not changed for many years. One reason patients with renal cancer are not... Read More

OHC Is Helping Raise Awareness of Ovarian Cancer

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

September is Ovarian Cancer Awareness Month and, as a proud sponsor of the Ovarian Cancer Alliance of Greater Cincinnati annual walk, OHC is taking this opportunity to help the Alliance raise public awareness of the signs and symptoms of and... Read More